Novel Therapeutic Approaches for Aggressive Prostate Cancer
侵袭性前列腺癌的新治疗方法
基本信息
- 批准号:10734381
- 负责人:
- 金额:$ 38.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-01 至 2028-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdenocarcinomaAggressive behaviorBindingCellsChemoresistanceClinicClinical TrialsCoupledDataGoalsImmuneImmune EvasionImmune checkpoint inhibitorImmune responseImmunocompetentImmunosuppressionInvadedMalignant NeoplasmsMalignant neoplasm of prostateMediatingMetastatic Prostate CancerModelingMonoclonal AntibodiesMorbidity - disease rateMusNPR2 geneNeoplasm MetastasisNeuroendocrine Prostate CancerNeuroendocrine TherapyNeuropilin-2OutcomePhenotypePredispositionPropertyReportingResistanceRoleSignal TransductionTherapeuticToxic effectTumor BurdenTumor ImmunityTumor PromotionUp-RegulationVascular Endothelial Growth FactorsWorkadvanced prostate cancerautocrinecell killingcheckpoint inhibitionchemotherapyeffective therapyexosomehumanized antibodyimprovedinhibitormanufacturemortalityneoplastic cellnonhuman primatenovelnovel therapeutic interventionpressureprogrammed cell death ligand 1programmed cell death protein 1prostate cancer modelreceptorresponsestem cellsstemnesstherapeutic targettranslational potentialtreatment strategytumortumor progression
项目摘要
Summary
The goal of this proposal is to develop a novel therapeutic strategy for the treatment of neuroendocrine
prostate cancer (NEPC) that has the potential for translation to the clinic. NEPC is an aggressive form of
prostate cancer that is associated with rapid progression, resistance to treatments and a very poor outcome.
Currently, there are no effective therapies for treating NEPC. This revised proposal focuses on the hypothesis
that programmed cell death 1 ligand (PD-L1) has a causal role in the stemness and metastatic propensity
associated with NEPC. Although PD-L1 is best known for its role in immune suppression, its tumor cell
intrinsic functions that are independent of immune suppression can also contribute to cancer progression.
Specifically, PD-L1 has been implicated in tumor stemness, invasion and metastasis and there is
circumstantial evidence that it contributes to these functions in NEPC, although a causal role has yet to be
demonstrated. This novel function of PD-L1 can be exploited to improve the therapy of NEPC based on
compelling evidence that VEGF/NRP2 signaling sustains the expression of PD-L1 in prostate cancer.
Inhibiting VEGF/NRP2 reduces stem cell properties and promotes a more differentiated phenotype that is more
susceptible to chemotherapy, and it is likely that the mechanism involves reducing PD-L1 expression. Also, a
humanized mAb is available that inhibits the binding of VEGF to NRP2. This mAb does not cause toxicity in
mice and non-human primates and is being manufactured for use in clinical trials. Of note, this mAb diminishes
the expression of PD-L1 significantly in models of NEPC. Together, these observations formulate a central
hypothesis: PD-L1 has a causal role in NEPC by sustaining stemness and facilitating metastasis (cell
autonomous PD-L1 function) and by promoting immune cell evasion (non-cell autonomous PD-L1 function).
Both critical functions of PD-L1 can be blocked by therapeutic targeting of VEGF binding to NRP2 to improve
the morbidity and mortality associated with NEPC. The first specific aim will investigate a therapeutic strategy
for inhibiting tumor cell intrinsic functions of PD-L1 to mitigate stemness and metastasis in NEPC that involves
blocking the binding of VEGF to NRP2. The second aim will investigate therapeutic strategies that target PD-
1-dependent and PD-1-independent functions of PD-L1 in NEPC by blocking the binding of VEGF to NPR2
using immune competent models. The data generated in this proposal have the potential to provide sufficient
evidence to justify the initiation of clinical trials using NRP2 inhibitors, especially the function-blocking Abs that
are the focus of the experimental approach.
概括
该提案的目标是开发一种新的治疗策略来治疗神经内分泌疾病
前列腺癌(NEPC)有可能转化为临床。 NEPC 是一种积极的形式
前列腺癌与快速进展、治疗耐药和预后极差有关。
目前,尚无治疗 NEPC 的有效疗法。这个修订后的提案侧重于假设
程序性细胞死亡 1 配体 (PD-L1) 在干性和转移倾向中具有因果作用
与 NEPC 相关。尽管 PD-L1 因其在免疫抑制中的作用而闻名,但它的肿瘤细胞
独立于免疫抑制的内在功能也可能导致癌症进展。
具体而言,PD-L1 与肿瘤干性、侵袭和转移有关,并且有
间接证据表明它有助于 NEPC 中的这些功能,尽管因果作用尚未确定
证明了。 PD-L1的这一新功能可用于改善基于NEPC的治疗
令人信服的证据表明 VEGF/NRP2 信号传导维持前列腺癌中 PD-L1 的表达。
抑制 VEGF/NRP2 会降低干细胞特性并促进更加分化的表型
对化疗敏感,其机制可能与降低 PD-L1 表达有关。另外,一个
人源化 mAb 可抑制 VEGF 与 NRP2 的结合。该 mAb 不会引起毒性
小鼠和非人类灵长类动物,正在生产用于临床试验。值得注意的是,这种单克隆抗体会减少
PD-L1在NEPC模型中显着表达。这些观察共同形成了一个中心
假设:PD-L1 通过维持干性和促进转移而在 NEPC 中发挥因果作用(细胞
自主 PD-L1 功能)和促进免疫细胞逃避(非细胞自主 PD-L1 功能)。
PD-L1 的这两个关键功能可以通过 VEGF 与 NRP2 结合的治疗靶向来阻断,从而改善
与 NEPC 相关的发病率和死亡率。第一个具体目标将研究治疗策略
用于抑制肿瘤细胞 PD-L1 的内在功能,以减轻 NEPC 的干细胞性和转移,涉及
阻断 VEGF 与 NRP2 的结合。第二个目标是研究针对 PD-的治疗策略
通过阻断 VEGF 与 NPR2 的结合,NEPC 中 PD-L1 的 1 依赖性和 PD-1 独立功能
使用免疫能力模型。本提案中生成的数据有可能提供足够的信息
证据证明启动使用 NRP2 抑制剂的临床试验是合理的,特别是功能阻断抗体
是实验方法的重点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arthur M Mercurio其他文献
Arthur M Mercurio的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arthur M Mercurio', 18)}}的其他基金
Integrin Regulation of Non-apoptotic Death in Breast Cancer
整合素对乳腺癌非凋亡死亡的调节
- 批准号:
10196990 - 财政年份:2018
- 资助金额:
$ 38.32万 - 项目类别:
Integrin Regulation of Non-apoptotic Death in Breast Cancer
整合素对乳腺癌非凋亡死亡的调节
- 批准号:
10439666 - 财政年份:2018
- 资助金额:
$ 38.32万 - 项目类别:
Nanosensor-Based Phenotypic Screening for Precision Therapy of Cancer Stem Cells
基于纳米传感器的表型筛选用于癌症干细胞的精准治疗
- 批准号:
9371612 - 财政年份:2017
- 资助金额:
$ 38.32万 - 项目类别:
Mechanisms of Carcinoma Differentiation and Invasion
癌分化和侵袭的机制
- 批准号:
8658042 - 财政年份:2012
- 资助金额:
$ 38.32万 - 项目类别:
Mechanisms of Carcinoma Differentiation and Invasion
癌分化和侵袭的机制
- 批准号:
8507623 - 财政年份:2012
- 资助金额:
$ 38.32万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 38.32万 - 项目类别: